MedTrace Logo

Mohs and Immunofluorescence for Malignant Melanoma In Situ

NCT02306512 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-01-07

No results posted yet for this study

Summary

The purpose of this study is to determine if immunofluorescence (IF) can effectively identify features of malignant melanoma in situ, on sun-damaged skin, in the setting of Mohs Micrographic Surgery.

Conditions

  • Lentigo Maligna
  • Melanoma In Situ

Interventions

PROCEDURE

H&E

Sample will be stained with H\&E according to standard procedures

PROCEDURE

IHC MART-1

Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.

PROCEDURE

IF MART-1

Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.

PROCEDURE

IF cocktail

The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.

Sponsors & Collaborators

  • University of Miami Sylvester Comprehensive Cancer Center

    collaborator OTHER

  • University of Miami

    lead OTHER

Principal Investigators

  • James Grichnik, MD, PhD · University of Miami

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306512 on ClinicalTrials.gov